title: Enhanced in vitro production of amyloid-like fibrils from mutant (S20G) islet amyloid polypeptide.
abstract: Islet amyloid polypeptide (IAPP, "amylin") is the amyloid-fibril-forming polypeptide in the islets of Langerhans associated with type 2 diabetes mellitus. A missense mutation in the IAPP gene associated with early-onset type 2 diabetes has been identified in the Japanese population. This mutation results in a glycine for serine substitution at position 20 of the mature IAPP molecule. Whether or not formation of islet amyloid with resulting destruction of islet tissue is the cause of this diabetes is yet not known. The present in vitro study was performed in order to investigate any influence of the amino acid substitution on the fibril formation capacity. Synthetic full-length wild type (IAPPwt) and mutant (IAPPS20G) as well as corresponding truncated peptides (position 18-29) were dissolved in dimethylsulfoxide (DMSO) or in 10% acetic acid at a concentration of 10 mg/mL and their fibril forming capacity was checked by Congo red staining, electron microscopy, a Congo red affinity assay and Thioflavine Tfluorometric assay. It was found that full-length and truncated IAPPS20G both formed more amyloid-like fibrils and did this faster compared to IAPPwt. The fibril morphology differed slightly between the preparations.
  
  
  CONCLUSIONS
  The amino acid substitution (S20G) is situated close to the region of the IAPP molecule implicated in the IAPP fibrillogenesis. The significantly increased formation of amyloid-like fibrils by IAPPS20G is highly interesting and may be associated with an increased islet amyloid formation in vivo and of fundamental importance in the pathogenesis of this specific form of diabetes.
authors.affiliation: Division of Molecular and Immunological Pathology, Linköping University, Sweden.
authors.forename: Z
authors.initials: Z
authors.lastname: Ma
authors.forename: G T
authors.initials: GT
authors.lastname: Westermark
authors.forename: S
authors.initials: S
authors.lastname: Sakagashira
authors.forename: T
authors.initials: T
authors.lastname: Sanke
authors.forename: A
authors.initials: A
authors.lastname: Gustavsson
authors.forename: H
authors.initials: H
authors.lastname: Sakamoto
authors.forename: U
authors.initials: U
authors.lastname: Engström
authors.forename: K
authors.initials: K
authors.lastname: Nanjo
authors.forename: P
authors.initials: P
authors.lastname: Westermark
mesh_terms: D000682:Amyloid / Q000096:biosynthesis* / Q000235:genetics* / Q000378:metabolism* / Q000648:ultrastructure; D003924:Diabetes Mellitus, Type 2 / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D006801:Humans; D066298:In Vitro Techniques; D058228:Islet Amyloid Polypeptide; D007515:Islets of Langerhans / Q000378:metabolism / Q000648:ultrastructure; D007700:Kinetics; D008854:Microscopy, Electron; D020125:Mutation, Missense; D010446:Peptide Fragments / Q000235:genetics / Q000378:metabolism
chemical_list: D000682:Amyloid; D058228:Islet Amyloid Polypeptide; D010446:Peptide Fragments